{"title":"Efficacy of intravenous alpha lipoic acid in the treatment of neuropatic pain due to carpal tunnel syndrome.","authors":"Öztürk Gülsah, Demiryurek Enes Bekir","doi":"10.18071/isz.76.0319","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong><p>In this study, we analyzed the effect of oral and oral + intravenous Alpha-lipoic acid (ALA) treatment on pain level and physical examination findings in patients diagnosed with carpal tunnel syndrome (CTS).</p>.</p><p><strong>Methods: </strong><p>A total of 115 patients patricipa­ted in the study. Physiotherapy and wrist splint were first applied to all patients diag­nosed with CTS in the study. 40 patients were treated with oral ALA after iv. ALA the­rapy, 35 patients received only oral ALA treatment and 40 patients did not receive any medication. The patients were divided into 3 groups as those who received only splint treatment and physiotherapy, those who received oral ALA treatment, and those who received oral ALA treatment after iv. treat­ment. All patients were assessed be­fore the treatment, and at the 1st and 3rd months of the treatment. In clinical assessment, visual analog scale (VAS) forms were filled to define the pain severity, the Boston symptom severity scale (BSSS) and Boston functional status scale (BFDS) were filled for evaluating symptoms and functional status. </p>.</p><p><strong>Results: </strong><p>VAS, BSSS and BFDS scores of the patients who were treated with intravenous and then oral ALA were found to be significantly lower at the end of both the 1st and 3rd months compared to the patients who received only oral ALA or no medication (p=0.001; p<0.001), (p=0.001; p<0.001), (p=0.006; p<0.001).</p>.</p><p><strong>Conclusion: </strong><p>We think that iv. ALA is effective in the treatment of symptoms associated with CTS.</p> <p> </p>.</p>","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"76 9-10","pages":"319-326"},"PeriodicalIF":0.9000,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ideggyogyaszati Szemle-Clinical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18071/isz.76.0319","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and purpose:
In this study, we analyzed the effect of oral and oral + intravenous Alpha-lipoic acid (ALA) treatment on pain level and physical examination findings in patients diagnosed with carpal tunnel syndrome (CTS).
.
Methods:
A total of 115 patients patricipated in the study. Physiotherapy and wrist splint were first applied to all patients diagnosed with CTS in the study. 40 patients were treated with oral ALA after iv. ALA therapy, 35 patients received only oral ALA treatment and 40 patients did not receive any medication. The patients were divided into 3 groups as those who received only splint treatment and physiotherapy, those who received oral ALA treatment, and those who received oral ALA treatment after iv. treatment. All patients were assessed before the treatment, and at the 1st and 3rd months of the treatment. In clinical assessment, visual analog scale (VAS) forms were filled to define the pain severity, the Boston symptom severity scale (BSSS) and Boston functional status scale (BFDS) were filled for evaluating symptoms and functional status.
.
Results:
VAS, BSSS and BFDS scores of the patients who were treated with intravenous and then oral ALA were found to be significantly lower at the end of both the 1st and 3rd months compared to the patients who received only oral ALA or no medication (p=0.001; p<0.001), (p=0.001; p<0.001), (p=0.006; p<0.001).
.
Conclusion:
We think that iv. ALA is effective in the treatment of symptoms associated with CTS.
期刊介绍:
The aim of Clinical Neuroscience (Ideggyógyászati Szemle) is to provide a forum for the exchange of clinical and scientific information for a multidisciplinary community. The Clinical Neuroscience will be of primary interest to neurologists, neurosurgeons, psychiatrist and clinical specialized psycholigists, neuroradiologists and clinical neurophysiologists, but original works in basic or computer science, epidemiology, pharmacology, etc., relating to the clinical practice with involvement of the central nervous system are also welcome.